(Q43042856)

12 November 2017

0 references

Selective serotonin reuptake inhibitors and adjuvant tamoxifen therapy: risk of breast cancer recurrence and mortality (English)

1 reference

12 November 2017

0 references

1 reference

Deirdre Cronin-Fenton

series ordinal

1

object named as

Deirdre Cronin-Fenton

1 reference

12 November 2017

Henrik T Sørensen

3

0 references

Timothy L Lash

series ordinal

2

object named as

Timothy L Lash

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 June 2010

1 reference

12 November 2017

1 reference

12 November 2017

volume

6

1 reference

12 November 2017

issue

6

1 reference

12 November 2017

page(s)

877-880

1 reference

Major depression after breast cancer: a review of epidemiology and treatment

12 November 2017

cites work

1 reference

Tamoxifen: catalyst for the change to targeted therapy

21 January 2018

1 reference

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes

21 January 2018

1 reference

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

21 January 2018

1 reference

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

21 January 2018

1 reference

Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen

21 January 2018

1 reference

No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications

21 January 2018

1 reference

Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram.

21 January 2018

1 reference

Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study

21 January 2018

1 reference

Tamoxifen, antidepressants, and CYP2D6: the conundrum continues

21 January 2018

1 reference

Breast cancer recurrence risk in relation to antidepressant use after diagnosis

21 January 2018

1 reference

Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition

21 January 2018

1 reference

SSRIs and tamoxifen. Why condemn fluoxetine?

21 January 2018

1 reference

Genotype-guided tamoxifen therapy: time to pause for reflection?

21 January 2018

1 reference

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine

21 January 2018

1 reference

Cytochrome P450 pharmacogenetics and cancer.

21 January 2018

1 reference

Impaired tamoxifen metabolism reduces survival in familial breast cancer patients

21 January 2018

1 reference

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

21 January 2018

1 reference

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

21 January 2018

1 reference

Antidepressant medications and change in mammographic density in postmenopausal women

21 January 2018

1 reference

Adherence to tamoxifen over the five-year course

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.10.65

1 reference

12 November 2017

1 reference